There are several papers on peptides like Thymosin alpha 1 for instance:
Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection
Here is what I got from prompting ChatGPT o3 about peptides to go along with Paxlovid for COVID:
Acute Phase (Days 1–5)
• Primary Goals:
• Focus on rest, hydration, and basic immune support.
• Peptide Focus:
• Thymosin Alpha 1: Initiate early to support a balanced immune response.
• LL-37: May be considered if early antiviral/antimicrobial support is indicated.
• Symptom Monitoring:
• Daily check of oxygen saturation, body temperature, and overall energy.
• If symptoms worsen, consider postponing additional peptides (BPC-157, Ac-SDKP, CJC-1295, Ipamorelin) until stabilization.
Subacute Phase (Days 5–14)
• Primary Goals:
• Gradually support tissue repair and reduce inflammation while monitoring recovery.
• Peptide Focus:
• BPC-157: Introduce for tissue repair if inflammatory symptoms (e.g., muscle soreness, gut discomfort) are noted.
• Ac-SDKP: Begin dosing to help mitigate fibrosis risks, especially if there are lingering respiratory or cardiovascular concerns.
• CJC-1295 & Ipamorelin: Consider initiating these to begin anabolic support and prevent muscle catabolism as activity levels slowly increase.
• Maintain Thymosin Alpha 1 if immune support remains necessary.
• Symptom Monitoring:
• Evaluate progress with markers like reduced inflammation, improved energy, and stable respiratory function.
• Continue checking vital signs (heart rate, oxygen saturation) and subjective measures (energy levels, muscle soreness).
Recovery and Return-to-Activity Phase (Day 14+)
• Primary Goals:
• Transition to a more active phase with gradual reintroduction of physical activity.
• Peptide Focus:
• Maintain CJC-1295 & Ipamorelin if anabolic support is still needed.
• BPC-157 can be tapered as tissue healing improves.
• Thymosin Alpha 1 might be reduced if immune markers are within normal limits.
• Ac-SDKP dosing can be re-evaluated based on any persistent lung or cardiac concerns.
• Symptom Monitoring:
• Monitor recovery with HRV (heart rate variability), resting heart rate, and lab tests (e.g., IGF-1 levels, inflammatory markers).
• Adjust exercise intensity based on recovery status, gradually increasing as tolerated.
I’m currently trying that along Paxlovid and I will test for hsCRP in a few weeks.